Algorae Pharmaceuticals Ltd
Company Profile
Business description
Algorae Pharmaceuticals Ltd is a clinical-stage pharmaceutical company developing transformative solutions for under met medical needs in the community. The firm develops AlgoraeOS, a closed-loop platform, leveraging computational tools to generate novel insights in silico that are being developed to initiate or accelerate therapeutic programs. The products of the company comprise AI-116, a novel combination drug candidate of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. The company is conceptualized to be a potential treatment for dementia, including Alzheimer’s disease, NTCELL is an alginate-coated capsule containing clusters of neonatal porcine choroid plexus cells. It also offers LP-003 Anti-obesity Drug and LC-002 migraine treatment.
Contact
525 Collins Street
Level 23, Rialto South Tower
MelbourneVIC3000
AUST: +61 422180317
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
48
Stocks News & Analysis
stocks
Chart of the Week: The market may be underestimating Amcor’s long term potential
stocks
Competitive pressures highlight need to lower costs for big 4 bank
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,034.50 | 50.40 | -0.55% |
| CAC 40 | 8,298.12 | 56.88 | 0.69% |
| DAX 40 | 24,277.33 | 104.13 | -0.43% |
| Dow JONES (US) | 48,254.82 | 326.86 | 0.68% |
| FTSE 100 | 9,870.08 | 41.34 | -0.42% |
| HKSE | 27,073.03 | 150.30 | 0.56% |
| NASDAQ | 23,406.46 | 61.84 | -0.26% |
| Nikkei 225 | 51,281.83 | 218.52 | 0.43% |
| NZX 50 Index | 13,597.87 | 73.86 | -0.54% |
| S&P 500 | 6,850.92 | 4.31 | 0.06% |
| S&P/ASX 200 | 8,753.40 | 46.00 | -0.52% |
| SSE Composite Index | 4,029.50 | 29.36 | 0.73% |